Back to top
more

Aveanna Healthcare (AVAH)

(Real Time Quote from BATS)

$8.20 USD

8.20
157,300

-0.03 (-0.37%)

Updated Sep 17, 2025 12:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Aveanna Healthcare Holdings Inc. (AVAH) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Encompass Health Corporation (EHC) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Benjamin Rains headshot

Buying the Best Top-Ranked Stocks in September

by Benjamin Rains

How investors can use a Zacks screen to help find some of the best Zacks Rank #1 (Strong Buy) stocks to buy in September and beyond.

Zacks Equity Research

Should You Buy Aveanna Healthcare (AVAH) After Golden Cross?

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Zacks Equity Research

Aveanna Healthcare Holdings Inc. (AVAH) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Earnings Estimates Rising for Aveanna (AVAH): Will It Gain?

by Zacks Equity Research

Aveanna Healthcare (AVAH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

What Makes Aveanna Healthcare (AVAH) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Aveanna (AVAH) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Aveanna (AVAH) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?

by Zacks Equity Research

Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Sweta Killa headshot

5 Stocks in QQQ ETF That Drove Nasdaq's Record Closing High

by Sweta Killa

QQQ surged on Nasdaq's record close as top holdings like AVAH and RUN posted explosive double-digit gains.

Zacks Equity Research

Aveanna Healthcare Holdings Inc. (AVAH) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Aveanna (AVAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Aveanna (AVAH) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?

by Zacks Equity Research

DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.

Zacks Equity Research

Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?

by Zacks Equity Research

Here is how Aveanna Healthcare (AVAH) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

Zacks Equity Research

Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Encompass Health to Expand Florida Presence With New 50-bed Facility

by Zacks Equity Research

EHC already boasts a massive footprint of 167 hospitals in 38 states and Puerto Rico.

Zacks Equity Research

Here Is Why Bargain Hunters Would Love Fast-paced Mover Aveanna (AVAH)

by Zacks Equity Research

Aveanna (AVAH) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs

by Zacks Equity Research

MD anticipates adjusted EBITDA to be between $220 million and $240 million in 2025.

Zacks Equity Research

Select Medical Lags Q1 Earnings Estimates, Lowers Revenue Outlook

by Zacks Equity Research

SEM reiterates that earnings for 2025 are likely to be between $1.09 and $1.19 per share.

Zacks Equity Research

Can Revenue Cycle Operations Drive DVA Stock Before Q1 Earnings?

by Zacks Equity Research

Continued strength in revenue cycle operations is likely to have boosted DaVita's top line in the first quarter despite supply challenges weighing on its performance.

Zacks Equity Research

TDOC Q1 Loss Narrower Than Estimates on Strong Integrated Care Unit

by Zacks Equity Research

Teladoc Health expects Integrated Care members to be between 101 million and 103 million in 2025.

Zacks Equity Research

Compared to Estimates, Aveanna (AVAH) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Aveanna (AVAH) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

The Pennant Group, Inc. (PNTG) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

The Pennant Group (PNTG) delivered earnings and revenue surprises of 22.73% and 3.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?